Indian Journal of Surgery

, Volume 81, Issue 5, pp 417–420 | Cite as

Complete Estrogen Blockade in Recalcitrant Mastalgia: A Pilot Study

  • Suhani SuhaniEmail author
  • Anurag Srivastava
  • Rajinder Parshad
  • V. Seenu
  • Kamal Kataria
  • Yashvant Rathode
Original Article


Mastalgia is the commonest cause of visit to the breast clinic. The present study was conducted to assess the efficacy of complete estrogen blockade (CEB) with centchroman and LHRH analog goserelin in the treatment of recalcitrant mastalgia. This is a prospective cohort study of 10 patients with recalcitrant mastalgia. Recalcitrant mastalgia was defined as bothersome breast pain with pain scores of six or more on breast pain chart, lasting for at least 7 days in a month even with therapy with first-line drugs for 3 months. The reduction of VAS to 3 or less at 4 weeks of initiation of treatment was the primary objective. Patients meeting the inclusion criteria received CEB for 3 months and were followed for 3 months to see for their symptom relief/recurrence. The pain scores were recorded. Side effects of the drug were noted. The mean pain score at start of study was 7.8. At 4 weeks of initiation of treatment, pain score became zero in five patients and reduced to less than three in three patients. These responders had maximum pain score of 3 during the follow-up period. None of the patients had adverse effect of the magnitude to request cessation of the treatment. There was no difference in characteristics of patients who responded from those who did not. No differences were seen among women with cyclical or noncyclical mastalgia. Complete estrogen blockade is safe and effective for treatment of recalcitrant mastalgia having a good post-treatment effect.


Mastalgia Complete estrogen blockade Centchroman Breast pain 



This work received funding support from Intramural Research Grant, All India Institute of Medical Sciences, New Delhi.


  1. 1.
    Rose DP, Boyar AP, Cohen C, Strong LE (1987) Effect of a low-fat diet on hormone levels in women with cystic breast disease. I. Serum steroids and gonadotropins. J Natl Cancer Inst 78:623–626PubMedGoogle Scholar
  2. 2.
    Kataria K, Dhar A, Srivastava A, Kumar S, Goyal A (2013) A systematic review of current understanding and management of mastalgia. Indian J Surg 76(3):217–222CrossRefGoogle Scholar
  3. 3.
    Gautam S, Srivastava A, Kataria K (2016) New breast pain chart for objective record of mastalgia. Indian J Surg 78:245–248CrossRefGoogle Scholar
  4. 4.
    (1992) Cyclical breast pain what works and what doesn’t. Drug Ther Bull 30:1–3Google Scholar
  5. 5.
    Tejwani PL, Srivastava A, Nerkar H, Dhar A, Hari S, Thulkar S, Chumber S, Kumar S (2011) Centchroman regresses mastalgia: a randomized comparison with danazol. Indian J Surg 73(3):199–205. CrossRefPubMedGoogle Scholar
  6. 6.
    Dhar A, Srivastava A (2007) Role of centchroman in regression of mastalgia and fibroadenoma. World J Surg 31(6):1178–1184CrossRefGoogle Scholar
  7. 7.
    Jain BK et al (2015) Centchroman vs tamoxifen for regression of mastalgia: a randomized controlled trial. Int J Surg 15:11–16CrossRefGoogle Scholar
  8. 8.
    Hamed H, Caleffi M, Chaudary MA, Fentiman IS (1990) LHRH analogue for treatment of recurrent and refractory mastalgia. Ann R Coll Surg Engl 72:221–224PubMedPubMedCentralGoogle Scholar
  9. 9.
    Mansel RE et al European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol 191(6):1942–1949CrossRefGoogle Scholar

Copyright information

© Association of Surgeons of India 2018

Authors and Affiliations

  1. 1.AIIMS DelhiNew DelhiIndia

Personalised recommendations